Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
08 12 2022
08 12 2022
Historique:
accepted:
23
08
2022
received:
21
02
2022
revised:
22
05
2022
pubmed:
3
9
2022
medline:
15
12
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African American men is thus far lacking in a prospective setting. This is a prospective study of the Decipher genomic classifier for National Comprehensive Cancer Network low- and intermediate-risk PCa. Study-eligible non-African American men were matched to African American men. Diagnostic biopsy specimens were processed to estimate Decipher scores. Samples accrued in NCT02723734, a prospective study, were interrogated to determine the genomic risk of reclassification (GrR) between conventional clinical risk classifiers and the Decipher score. The final analysis included a clinically balanced cohort of 226 patients with complete genomic information (113 African American men and 113 non-African American men). A higher proportion of African American men with National Comprehensive Cancer Network-classified low-risk (18.2%) and favorable intermediate-risk (37.8%) PCa had a higher Decipher score than non-African American men. Self-identified African American men were twice more likely than non-African American men to experience GrR (relative risk [RR] = 2.23, 95% confidence interval [CI] = 1.02 to 4.90; P = .04). In an ancestry-determined race model, we consistently validated a higher risk of reclassification in African American men (RR = 5.26, 95% CI = 1.66 to 16.63; P = .004). Race-stratified analysis of GrR vs non-GrR tumors also revealed molecular differences in these tumor subtypes. Integration of genomic classifiers with clinically based risk classification can help identify the subset of African American men with localized PCa who harbor high genomic risk of early metastatic disease. It is vital to identify and appropriately risk stratify the subset of African American men with aggressive disease who may benefit from more targeted interventions.
Sections du résumé
BACKGROUND
Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African American men is thus far lacking in a prospective setting.
METHODS
This is a prospective study of the Decipher genomic classifier for National Comprehensive Cancer Network low- and intermediate-risk PCa. Study-eligible non-African American men were matched to African American men. Diagnostic biopsy specimens were processed to estimate Decipher scores. Samples accrued in NCT02723734, a prospective study, were interrogated to determine the genomic risk of reclassification (GrR) between conventional clinical risk classifiers and the Decipher score.
RESULTS
The final analysis included a clinically balanced cohort of 226 patients with complete genomic information (113 African American men and 113 non-African American men). A higher proportion of African American men with National Comprehensive Cancer Network-classified low-risk (18.2%) and favorable intermediate-risk (37.8%) PCa had a higher Decipher score than non-African American men. Self-identified African American men were twice more likely than non-African American men to experience GrR (relative risk [RR] = 2.23, 95% confidence interval [CI] = 1.02 to 4.90; P = .04). In an ancestry-determined race model, we consistently validated a higher risk of reclassification in African American men (RR = 5.26, 95% CI = 1.66 to 16.63; P = .004). Race-stratified analysis of GrR vs non-GrR tumors also revealed molecular differences in these tumor subtypes.
CONCLUSIONS
Integration of genomic classifiers with clinically based risk classification can help identify the subset of African American men with localized PCa who harbor high genomic risk of early metastatic disease. It is vital to identify and appropriately risk stratify the subset of African American men with aggressive disease who may benefit from more targeted interventions.
Identifiants
pubmed: 36053178
pii: 6687132
doi: 10.1093/jnci/djac162
pmc: PMC9745424
doi:
Banques de données
ClinicalTrials.gov
['NCT02723734']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1656-1664Subventions
Organisme : NCI NIH HHS
ID : P20 CA233255
Pays : United States
Organisme : NIH HHS
ID : P20-CA233255
Pays : United States
Organisme : NIH HHS
ID : P30-CA076292
Pays : United States
Informations de copyright
Published by Oxford University Press 2022.
Références
Clin Cancer Res. 2021 Jan 1;27(1):320-329
pubmed: 33037017
J Urol. 2017 Mar;197(3 Pt 1):627-631
pubmed: 27582435
JAMA Netw Open. 2021 Nov 1;4(11):e2132388
pubmed: 34748010
Eur Urol Oncol. 2022 Feb;5(1):18-29
pubmed: 34446369
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
J Urol. 2020 Jul;204(1):82-90
pubmed: 31977261
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
JAMA Oncol. 2021 Apr 1;7(4):544-552
pubmed: 33570548
Genome Res. 2009 Sep;19(9):1655-64
pubmed: 19648217
Nat Commun. 2013;4:2612
pubmed: 24113773
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):136-143
pubmed: 31455846
J Clin Oncol. 2013 Aug 20;31(24):2991-7
pubmed: 23775960
J Clin Oncol. 2018 Feb 20;36(6):581-590
pubmed: 29185869
J Urol. 2005 Jun;173(6):1938-42
pubmed: 15879786
Eur Urol. 2021 Mar;79(3):374-383
pubmed: 33293078
J Clin Oncol. 2015 Sep 1;33(25):2789-96
pubmed: 26195723
Nat Commun. 2017 Jul 24;8(1):103
pubmed: 28740126
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):419-428
pubmed: 31844180
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Eur Urol. 2019 Jun;75(6):1038-1040
pubmed: 30683576
J Urol. 2019 Aug;202(2):247-255
pubmed: 31107158
Nat Commun. 2016 Feb 29;7:10798
pubmed: 26924072